Xerese

Medivir (STO: MVIRB) and Meda today announced an agreement for the commercialization of Medivir's cold sore product which will be marketed in North America under the trade name Xerese ™.

THE MEDICAL NEWS Editors 2010

In June 2011, Valeant Pharma also acquired rights for Canada, US and Mexico for Elidel cream and Xerese cream from an international specialty pharmaceutical company, Meda.

unknown title 2011

Valeant and Meda have also entered into a development agreement for life cycle management of both Elidel and Xerese.

unknown title 2011

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program Medivir, Meda announce agreement to commercialize Medivir's cold sore product, Xerese >

THE MEDICAL NEWS Editors 2010

Medivir, Meda announce agreement to commercialize Medivir's cold sore product, Xerese

THE MEDICAL NEWS Editors 2010

Based on strong clinical data, Xerese ™ was given a label, which differentiates it from other topical cold sore products currently on the market.

THE MEDICAL NEWS Editors 2010

Xerese ™ - a combination product of acyclovir and hydrocortisone - was granted FDA marketing approval in July 2009.

THE MEDICAL NEWS Editors 2010

Xerese ™ (Xerclear ™ in Europe) - a patented combination of 5% acyclovir and 1% hydrocortisone in Medivir's proprietary cream formulation - is a topical product for the treatment of recurrent herpes labialis.

THE MEDICAL NEWS Editors 2010

In addition to funding the commercial development of Xerese ™, Meda will pay USD 5 million in up-front and pre-launch milestones and double-digit royalties on sales to Medivir for the exclusive rights.

THE MEDICAL NEWS Editors 2010

Under the terms of the agreement, Meda is granted the exclusive rights to market, sell and distribute Xerese ™ in the United States, Canada and Mexico for the treatment of cold sores

THE MEDICAL NEWS Editors 2010